Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Next Previous
Trial Profile

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary) ; Selinexor (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms XPORT-MM-031

Most Recent Events

  • 14 May 2026 According to a Karyopharm Therapeutics media release, topline data from the event-driven, Phase 3 XPORT-MM-031 (EMN29) trial, expected in the second half of 2026.
  • 06 Oct 2025 According to a Karyopharm Therapeutics media release, company continues to follow patients that are enrolled in the Phase 3 XPORT-MM-031 (EMN29) trial and expects to report top-line data from this event-driven trial in the first half of 2026.
  • 12 May 2025 According to a Karyopharm Therapeutics media release, enrollment of approximately 120 patients in this Phase 3 was completed in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top